PLX - MCAP CO - Protalix BioTherapeutics

The primary risk for Protalix BioTherapeutics (PLX) stems from its reliance on a single Gaucher disease therapy and the competitive landscape. The company expands its business through partnerships with global leaders, utilizing the ProCellEx system for protein production. Market capitalization stands at 0.22. This price chart reflects the asset's dynamics, with resilience supported by the humanitarian status of sales despite instability in the Middle East.

Market capitalization represents the aggregate value of all a company's shares, defining the current market scale of the business. By analyzing the capitalization trend of Protalix BioTherapeutics (PLX), an investor can observe the dynamics of the asset's equilibrium price. This metric is calculated as the product of the share price and the number of outstanding shares, demonstrating sensitivity to market expectations. For Protalix BioTherapeutics (PLX), this metric reflects the potential of the ProCellEx platform. Reducing costs in plant-based protein production creates a foundation for the long-term growth of the business value.